Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Robert Ashworth?

Robert W. Ashworth

Vice President, Global Regulatory Affairs

Otsuka America Pharmaceutical , Inc.

HQ Phone:  (203) 527-9479

Direct Phone: (609) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Otsuka America Pharmaceutical , Inc.

508 Carnegie Center

Princeton, New Jersey,08540

United States

Company Description

OAPI commercializes Otsuka-discovered and in-licensed products in North America. OPDC clinically develops and registers innovative healthcare products on a global basis. OMML is a basic research center investigating pharmacological compounds. OAPI, OPDC,... more.

Find other employees at this company (3,467)

Background Information

Employment History

Vice President, Global Regulatory Affairs

NPS Pharmaceuticals , Inc.


Vice President of Corporate Quality and Regulatory Affairs

Forest Laboratories , Inc.


Vice President, Regulatory Affairs

Biovail Corporation


Web References(6 Total References)


www.otsuka-us.com

Robert Ashworth, Ph.D.
Vice President, Global Regulatory Affairs


www.otsuka-us.com [cached]

Robert Ashworth, Ph.D.
Vice President, Global Regulatory Affairs Robert Ashworth, Ph.D. Vice President, Global Regulatory Affairs Robert Ashworth is Vice-President, Global Regulatory Affairs at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), where he is responsible for leading regulatory affairs initiatives for investigational and marketed products and overseeing the regulatory interactions with external partners. Dr. Ashworth has a lengthy record of achievement reflecting more than 30 years of experience, from chemistry research to corporate quality and compliance and regulatory affairs. His drug development and regulatory experience includes small molecules, biologic proteins and antibodies. Prior to joining Otsuka in December 2010, he served as Vice-President, Regulatory Affairs at Biovail Corporation and, before that, he was Vice President, Regulatory Affairs and Corporate Quality at Forest Laboratories, Inc. He also held positions of increasing responsibility at BASF (Knoll Pharmaceutical Company) and Ciba-Geigy Corporation. Dr. Ashworth received a Bachelor of Science degree in chemistry from St. John's University (New York) and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology.


www.bio-forum.com

Robert Ashworth
Vice-President, Global Regulatory Affairs,NPS Pharmaceuticals, Inc.


ca.hotstocked.com

In accepting the award, Dr. Robert Ashworth, Biovails Vice-President, Regulatory Affairs said, This award to Biovail represents the culmination of a collaborative effort among investigators, patient advocacy groups, industry and FDA.
We gratefully acknowledge the contribution of another honoree, the Huntington's Disease Society of America, in educating patients and caregivers about the appropriate use of Xenazine. Dr. Ashworth added, The greatest validation of efforts in drug development derives from satisfying an unmet medical need.


ir.valeant.com

In accepting the award, Dr. Robert Ashworth, Biovail's Vice-President, Regulatory Affairs said, "This award to Biovail represents the culmination of a collaborative effort among investigators, patient advocacy groups, industry and FDA.
We gratefully acknowledge the contribution of another honoree, the Huntington's Disease Society of America, in educating patients and caregivers about the appropriate use of Xenazine." Dr. Ashworth added, "The greatest validation of efforts in drug development derives from satisfying an unmet medical need.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory